Nerdwallet Inc vs Novavax Inc — how do they compare? Nerdwallet Inc trades at $9.68 (market cap $625.17M), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 2.9× Nerdwallet Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Novavax Inc for 59 Days on average.
| NRDS | NVAX | |
|---|---|---|
Market Cap | $625.17M | $1.82B |
Volume | 1,321,316 | 6,198,505 |
Sector | Media | Health |
52-Week High | $15.93 | $12.56 |
52-Week Low | $7.58 | $6.22 |
Typical Hold Time | 45 Days | 59 Days |
Enterprise Value | $539.47M | $1.39B |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.74, up 7.21% today, showing strong momentum despite a recent Q2 2026 earnings miss. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Fundamentally, the company demonstrates robust revenue growth from $539M in 2022 to $837M in 2025, with improving profitability margins. Recent news highlights the company's Financial Resilience Index publications and Wall Street's positive outlook.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key opportunities include continued revenue growth and margin expansion, while risks involve organic search pressure in core products and macroeconomic sensitivity. The stock presents a compelling value proposition with attractive valuation multiples.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →